S&P 500
7,666.60
+35.13
+0.46%
Dow
53,061.95
+295.05
+0.56%
Nasdaq
26,217.83
+118.06
+0.45%
NYSE Composite
24,495.55
+146.25
+0.60%
Russell 2000
2,953.17
+33.04
+1.13%
VIX
15.38
+0.18
+1.18%
JNJ · Johnson & Johnson
NEW YORK STOCK EXCHANGE, INC. - Real Time Price • USD
Johnson & Johnson (JNJ)
NEW YORK STOCK EXCHANGE, INC.
Pharmaceuticals
$275.42
+4.12
(+1.52%)
● At close: September 2 at 4:00:00 PM EDT
$276.36
+1.02
(+0.37%)
Pre-Market:
8:21:50 AM EDT
DAY'S RANGE
$275.42
$273.56
$281.00
52-WEEK RANGE
$275.42
$173.33
$281.07
What's happening
- JNJ is up 1.52% today, trading at $275.42. — Live quote
- Volume today (356,304) is well below its 3-month average of 7,786,730. (Finnhub fundamentals)
- Last quarter's EPS beat estimates: $2.90 actual vs. $2.87 estimated (+0.9%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 7
Buy 15
Hold 9
Sell 0
Strong sell 0
Aggregate ratings for 2026-09-01 (31 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
JNJ
+32.98%
vs S&P 500
+20.78%
1-YEAR RETURN
JNJ
+54.61%
vs S&P 500
+35.75%
6-MONTH RETURN
JNJ
+10.78%
3-MONTH RETURN
JNJ
+23.47%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$2.90
Est. $2.87
BEAT +0.9%
2026-04-26 (Q1 2026)
$2.70
Est. $2.69
BEAT +0.3%
2026-01-26 (Q4 2025)
$2.46
Est. $2.46
MISS -0.1%
2025-10-26 (Q3 2025)
$2.80
Est. $2.78
BEAT +0.5%
Valuation Measures & Ratios
Enterprise Value4$670.76B
Forward P/E520.74
PEG Ratio63.39
Price / Sales (TTM1)6.43
Price / Book77.32
EV4 / Revenue6.85
EV4 / EBITDA20.36
Profit Margin21.48%
Operating Margin25.73%
Return on Equity (ROE8)25.74%
Return on Assets (ROA9)10.60%
Avg Volume (3M)7,786,730
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $617.05B | $581.84B | $427.11B | $357.92B | $381.74B |
| P/E | 28.76 | 21.61 | 17.52 | 14.97 | 17.65 |
| Price/Sales | 6.35 | 6.21 | 4.64 | 3.95 | 4.33 |
| Price/Book | 7.26 | 7.17 | 5.39 | 4.56 | 4.89 |
| EV/Revenue | 6.65 | 6.57 | 4.94 | 4.31 | 4.48 |
| ROE | 25.25% | 33.16% | 30.76% | 30.48% | 27.70% |
| ROA | 10.67% | 13.40% | 12.65% | 12.37% | 11.17% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E and PEG aren't shown here — both need historical analyst-consensus estimates, which no free source provides; see the current-period figures above instead.
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short21,591,738
Change from Prior Settlement-15.02%
% of Float—
Days to Cover (Short Ratio)3.33
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-08-14. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Signals describe daily price patterns—not the company’s value and not a recommendation to buy or sell. Read several together; no single indicator predicts what happens next. “Overbought” and “oversold” are conditions, not promises of a reversal.
Indicators None active
Loading chart…
Free IEX historical data only goes back to ~2021 — 5Y/Full show whatever's actually available, not a promise of that much history. Indicators are computed client-side from these same price bars; earnings markers ("E") come from Finnhub's free tier (~last 4 quarters + next upcoming) — older quarters aren't available. The move-highlight dots are a heuristic (|% change| vs rolling volatility) with a best-effort headline lookup, not a claim of causation.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 6.6% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is 21.5%. Finnhub fundamentals ↗
- Trailing 52-week price return is +54.6%. Finnhub market metrics ↗
Potential concerns
- Latest SEC filing is Form 4, filed 2026-08-18; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on JNJ
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $25.31B | $24.06B | $23.99B | $23.74B | $21.89B | $22.47B | $22.45B | $21.38B |
| Gross profit | $17.26B | $15.96B | $16.69B | $16.11B | $14.54B | $15.51B | $15.58B | $14.87B |
| Operating income | — | — | — | — | — | — | — | — |
| Net income | $5.53B | $5.24B | $5.15B | $5.54B | $11.00B | $2.69B | $4.69B | $3.25B |
| EPS (diluted) | $2.27 | $2.14 | $2.12 | $2.29 | $4.54 | $1.11 | $1.93 | $1.34 |
| EPS (basic) | $2.30 | $2.17 | $2.14 | $2.30 | $4.57 | $1.12 | $1.95 | $1.35 |
| Net margin | $22 | $22 | $21 | $23 | $50 | $12 | $21 | $15 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $201.06B | $200.89B | $199.21B | $192.82B | $193.39B | $193.67B | $180.10B | $178.29B |
| Total liabilities | $116.09B | $119.71B | $117.67B | $113.54B | $114.92B | $115.56B | $108.61B | $108.13B |
| Stockholders' equity | $84.97B | $81.19B | $81.54B | $79.28B | $78.47B | $78.11B | $71.49B | $70.16B |
| Total current assets | $59.77B | $59.17B | $55.62B | $54.61B | $54.50B | $71.55B | $55.89B | $53.25B |
| Total current liabilities | $54.90B | $57.72B | $54.13B | $50.87B | $54.18B | $56.90B | $50.32B | $51.76B |
| Cash & equivalents | $20.42B | $21.69B | $19.71B | $18.23B | $18.58B | $38.47B | $24.11B | $19.98B |
| Marketable securities (current) | $336.0M | $363.0M | $393.0M | $331.0M | $303.0M | $307.0M | $417.0M | $317.0M |
| Accounts receivable | $19.05B | $17.72B | $17.18B | $17.61B | $17.85B | $16.02B | $14.84B | $16.17B |
| Inventory | $15.14B | $14.58B | $14.19B | $14.15B | $13.41B | $12.66B | $12.44B | $12.60B |
| Property, plant & equipment | $23.58B | $23.27B | $23.17B | $22.34B | $21.95B | $20.87B | $20.52B | $20.48B |
| Goodwill | $48.48B | $48.56B | $48.77B | $48.05B | $48.12B | $44.47B | $44.20B | $44.80B |
| Intangible assets | $48.23B | $49.06B | $50.40B | $48.74B | $49.84B | $36.76B | $37.62B | $39.49B |
| Other non-current assets | $14.27B | $14.11B | $14.37B | $12.42B | $12.19B | $11.53B | $11.41B | $10.92B |
| Accounts payable | $9.22B | $10.46B | $11.99B | $9.62B | $9.46B | $9.54B | $10.31B | $8.95B |
| Accrued liabilities | $9.46B | $7.40B | $8.59B | $7.60B | $7.40B | $7.91B | $8.55B | $11.45B |
| Short-term debt | $11.69B | $17.46B | $8.49B | $6.39B | $11.53B | $13.90B | $5.98B | $4.46B |
| Long-term debt | $37.34B | $37.53B | $39.44B | $39.41B | $39.23B | $38.35B | $30.65B | $31.29B |
| Other non-current liabilities | $10.10B | $10.21B | $9.87B | $9.93B | $10.26B | $10.44B | $17.55B | $14.92B |
| Common stock & paid-in capital | $3.12B | $3.12B | $3.12B | $3.12B | $3.12B | $3.12B | $3.12B | $3.12B |
| Retained earnings | $171.66B | $169.16B | $168.98B | $167.28B | $165.37B | $162.63B | $155.79B | $155.18B |
| Accumulated other comprehensive income (loss) | -$13.95B | -$14.83B | -$14.93B | -$15.24B | -$14.30B | -$11.74B | -$11.74B | -$12.52B |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $8.62B | $2.51B | $7.31B | $9.17B | $3.88B | $4.17B | $6.98B | $7.99B |
| Investing cash flow | -$1.11B | -$1.04B | -$4.49B | -$542.0M | -$18.26B | -$297.0M | -$1.32B | -$3.13B |
| Financing cash flow | -$8.78B | $530.0M | -$1.37B | -$8.93B | -$5.67B | $10.42B | -$1.34B | -$9.88B |
| Free cash flow | $7.29B | $1.47B | $5.47B | $8.01B | $2.83B | $3.38B | $5.37B | $6.96B |
| Capital expenditures | $1.32B | $1.05B | $1.84B | $1.16B | $1.04B | $795.0M | $1.61B | $1.03B |
| Depreciation & amortization | $1.96B | $2.00B | $2.01B | $1.78B | $1.94B | $1.77B | $1.90B | $1.85B |
| Share-based compensation | $458.0M | $300.0M | $309.0M | $347.0M | $410.0M | $288.0M | $238.0M | $295.0M |
| Deferred income taxes | -$479.0M | $159.0M | -$3.68B | $2.22B | $825.0M | $2.17B | -$16.0M | $90.0M |
| Change in accounts receivable | $1.35B | $595.0M | -$391.0M | -$111.0M | $1.36B | $926.0M | -$853.0M | $96.0M |
| Change in inventory | $571.0M | $431.0M | $46.0M | $748.0M | $510.0M | $146.0M | $90.0M | $299.0M |
| Purchases of investments | $155.0M | $144.0M | $243.0M | $246.0M | $180.0M | $251.0M | $262.0M | $280.0M |
| Other investing activities | $139.0M | $54.0M | $63.0M | $33.0M | $36.0M | $30.0M | $72.0M | $16.0M |
| Share repurchases | $221.0M | $4.03B | $1.92B | $1.90B | $0 | $2.13B | $282.0M | $539.0M |
| Debt issued | $0 | $0 | $0 | $0 | $0 | $9.14B | $0 | $1.0M |
| Debt repaid | — | — | $1.76B | — | — | — | $1.45B | — |
| Other financing activities | $0 | -$588.0M | -$26.0M | -$49.0M | $1.0M | $40.0M | $0 | -$75.0M |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Jan '23 | Jan '22 |
|---|---|---|---|---|---|
| Revenue | $94.19B | $88.82B | $85.16B | $79.99B | $78.74B |
| Gross profit | $63.94B | $61.35B | $58.61B | $55.39B | $55.34B |
| Operating income | — | — | — | — | — |
| Net income | $26.80B | $14.07B | $35.15B | $17.94B | $20.88B |
| EPS (diluted) | $11.03 | $5.79 | $13.72 | $6.73 | $7.81 |
| EPS (basic) | $11.13 | $5.84 | $13.88 | $6.83 | $7.93 |
| Net margin | $28 | $16 | $41 | $22 | $27 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Jan '23 | Jan '22 |
|---|---|---|---|---|---|
| Total assets | $199.21B | $180.10B | $167.56B | $187.38B | $182.02B |
| Total liabilities | $117.67B | $108.61B | $98.78B | $110.57B | $108.00B |
| Total current assets | $55.62B | $55.89B | $53.49B | $55.29B | $60.98B |
| Total current liabilities | $54.13B | $50.32B | $46.28B | $55.80B | $45.23B |
| Cash & equivalents | $19.71B | $24.11B | $21.86B | $12.89B | $14.49B |
| Marketable securities (current) | $393.0M | $417.0M | $1.07B | $9.39B | $17.12B |
| Accounts receivable | $17.18B | $14.84B | $14.87B | $14.04B | $15.28B |
| Inventory | $14.19B | $12.44B | $11.18B | $10.27B | $10.39B |
| Property, plant & equipment | $23.17B | $20.52B | $19.90B | $17.98B | $18.96B |
| Goodwill | $48.77B | $44.20B | $36.56B | $36.05B | $25.44B |
| Intangible assets | $50.40B | $37.62B | $34.17B | $38.49B | $46.39B |
| Other non-current assets | $14.37B | $11.41B | $14.15B | $9.21B | $10.22B |
| Accounts payable | $11.99B | $10.31B | $9.63B | $9.89B | $11.05B |
| Accrued liabilities | $8.59B | $8.55B | $10.21B | $10.72B | $13.61B |
| Short-term debt | $8.49B | $5.98B | $3.45B | $12.76B | $3.77B |
| Long-term debt | $39.44B | $30.65B | $25.88B | $26.89B | $29.98B |
| Other non-current liabilities | $9.87B | $17.55B | $13.40B | $10.15B | $10.69B |
| Common stock & paid-in capital | $3.12B | $3.12B | $3.12B | $3.12B | $3.12B |
| Retained earnings | $168.98B | $155.79B | $153.84B | $128.34B | $123.06B |
| Accumulated other comprehensive income (loss) | -$14.93B | -$11.74B | -$12.53B | -$12.97B | -$13.06B |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Jan '23 | Jan '22 |
|---|---|---|---|---|---|
| Operating cash flow | $24.53B | $24.27B | $22.79B | $21.19B | $23.41B |
| Investing cash flow | -$23.59B | -$18.60B | $878.0M | -$12.37B | -$8.68B |
| Financing cash flow | -$5.54B | -$3.13B | -$15.82B | -$8.87B | -$14.05B |
| Free cash flow | $19.70B | $19.84B | $18.25B | $17.18B | $19.76B |
| Capital expenditures | $4.83B | $4.42B | $4.54B | $4.01B | $3.65B |
| Depreciation & amortization | $7.50B | $7.34B | $7.49B | $6.97B | $7.39B |
| Share-based compensation | $1.35B | $1.18B | $1.16B | $1.14B | $1.14B |
| Deferred income taxes | $1.54B | -$2.18B | -$4.19B | -$1.66B | -$2.08B |
| Change in accounts receivable | $1.78B | $406.0M | $624.0M | $1.29B | $2.40B |
| Change in inventory | $1.45B | $1.13B | $1.32B | $2.53B | $1.25B |
| Purchases of investments | $920.0M | $1.73B | $10.91B | $32.38B | $30.39B |
| Other investing activities | $162.0M | $174.0M | -$12.0M | $229.0M | $508.0M |
| Share repurchases | $5.95B | $2.43B | $5.05B | $6.04B | $3.46B |
| Debt issued | $9.14B | $6.66B | $0 | $2.0M | $5.0M |
| Debt repaid | $1.76B | $1.45B | $1.55B | $2.13B | $1.80B |
| Other financing activities | -$34.0M | -$38.0M | -$269.0M | $93.0M | $114.0M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding JNJ as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Source: Business Quant SEC Form 13F · report period 2026-06-30 · 31 filers
Held by These Filers49.4%
Shares Outstanding2,407,400,000
| Filer | Shares | Value | % Out | Qtr Change | Filed |
|---|---|---|---|---|---|
| BlackRock, Inc. | 212,098,264 | $53.87B | 8.81% | -0.6% | 2026-08-07 |
| VANGUARD CAPITAL MANAGEMENT LLC | 157,226,374 | $39.93B | 6.53% | +0.4% | 2026-06-30 |
| State Street Corp | 133,776,025 | $33.98B | 5.56% | +0.2% | 2026-08-07 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 64,370,816 | $16.35B | 2.67% | +1.3% | 2026-06-30 |
| GEODE CAPITAL MANAGEMENT, LLC | 59,086,417 | $14.97B | 2.45% | -0.1% | 2026-08-12 |
| Jpmorgan Chase & Co | 58,301,609 | $15.07B | 2.42% | -7.6% | 2026-08-12 |
| Morgan Stanley | 44,808,254 | $11.38B | 1.86% | +0.2% | 2026-08-11 |
| NORGES BANK | 31,825,084 | $8.08B | 1.32% | +0.0% | 2026-08-12 |
| STATE FARM MUTUAL AUTOMOBILE INSURANCE CO | 31,590,952 | $8.02B | 1.31% | +0.0% | 2026-07-28 |
| Northern Trust Corp | 28,792,064 | $7.31B | 1.20% | -1.8% | 2026-08-12 |
| Bank Of America Corp /De/ | 23,438,141 | $5.95B | 0.97% | -8.1% | 2026-08-14 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 22,996,878 | $5.8M | 0.96% | +39.4% | 2026-08-14 |
| FMR LLC | 22,595,566 | $5.74B | 0.94% | -8.8% | 2026-08-13 |
| WELLINGTON MANAGEMENT GROUP LLP | 22,588,696 | $5.74B | 0.94% | +12.5% | 2026-08-14 |
| Bank of New York Mellon Corp | 21,683,347 | $5.51B | 0.90% | -0.6% | 2026-08-06 |
| Goldman Sachs Group Inc | 19,722,544 | $5.01B | 0.82% | +9.2% | 2026-08-14 |
| Legal & General Group Plc | 19,286,904 | $4.90B | 0.80% | -0.3% | 2026-08-14 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 19,126,165 | $4.86B | 0.79% | -0.3% | 2026-08-14 |
| Sixth Street Partners Management Company, L.P. | 19,126,165 | $4.86B | 0.79% | +0.0% | 2026-08-13 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 18,416,123 | $4.68B | 0.76% | -6.2% | 2026-08-13 |
| Wells Fargo & Company/Mn | 17,374,433 | $4.41B | 0.72% | +2.7% | 2026-08-14 |
| Invesco Ltd. | 15,674,093 | $3.98B | 0.65% | +4.2% | 2026-08-13 |
| DEUTSCHE BANK AG\ | 15,661,323 | $3.98B | 0.65% | +8.5% | 2026-08-07 |
| DIMENSIONAL FUND ADVISORS LP | 15,385,556 | $3.91B | 0.64% | -2.8% | 2026-08-11 |
| Capital World Investors | 15,215,015 | $3.86B | 0.63% | +29.5% | 2026-08-07 |
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-02-27 to 2026-08-17
Recent transactions
- Insiders have net sold 235,743 shares over the last 182 days, across 0 purchases and 9 sales.
- Most recent: Taubert Jennifer L (EVP, WWC. Innovative Medicine) — Option exercise of 15,000 shares on 2026-08-17.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)235,743 sh(9 txns)
Net Shares-235,743
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Taubert Jennifer L | EVP, WWC. Innovative Medicine | Option exercise | 2026-08-17 | 15,000 |
| Duato Joaquin | CEO and Chairman of the Board | Option exercise | 2026-08-13 | 123,291 |
| Forminard Elizabeth | EVP, Chief Legal Officer | Option exercise | 2026-08-06 | 9,344 |
| Broadhurst Vanessa | EVP, Global Corp Affairs | Option exercise | 2026-07-20 | 11,129 |
| Wengel Kathryn E | EVP, Chief TO and Risk Officer | Option exercise | 2026-06-11 | 10,000 |
| REED JOHN C | EVP, Innovative Medicine, R&D | Option exercise | 2026-05-01 | 25,255 |
| Decker Robert J | VP Corporate Controller | Option exercise | 2026-02-27 | 4,075 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-17 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | Option exercise | 15,000 | $115.67 |
| 2026-08-17 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | Open market sale | 15,000 | $263.36 |
| 2026-08-13 | Duato Joaquin | CEO and Chairman of the Board | Option exercise | 123,291 | $115.67 |
| 2026-08-13 | Duato Joaquin | CEO and Chairman of the Board | Open market sale | 20,976 | $262.00 |
| 2026-08-13 | Duato Joaquin | CEO and Chairman of the Board | Open market sale | 102,315 | $261.00 |
| 2026-08-06 | Forminard Elizabeth | EVP, Chief Legal Officer | Option exercise | 9,344 | $131.94 |
| 2026-08-06 | Forminard Elizabeth | EVP, Chief Legal Officer | Open market sale | 9,344 | $257.75 |
| 2026-08-06 | Forminard Elizabeth | EVP, Chief Legal Officer | Open market sale | 6,574 | $255.93 |
| 2026-08-05 | Duato Joaquin | CEO and Chairman of the Board | Open market sale | 41,957 | $258.06 |
| 2026-08-05 | Duato Joaquin | CEO and Chairman of the Board | Open market sale | 6,523 | $258.74 |
| 2026-07-20 | Broadhurst Vanessa | EVP, Global Corp Affairs | Option exercise | 11,129 | $129.51 |
| 2026-07-20 | Broadhurst Vanessa | EVP, Global Corp Affairs | Option exercise | 11,925 | $131.94 |
| 2026-07-20 | Broadhurst Vanessa | EVP, Global Corp Affairs | Open market sale | 23,054 | $251.27 |
| 2026-06-11 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Option exercise | 10,000 | $115.67 |
| 2026-06-11 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Open market sale | 10,000 | $241.15 |
| 2026-05-01 | REED JOHN C | EVP, Innovative Medicine, R&D | Option exercise | 25,255 | $0.00 |
| 2026-05-01 | REED JOHN C | EVP, Innovative Medicine, R&D | Tax withholding | 11,002 | $229.85 |
| 2026-02-27 | Decker Robert J | VP Corporate Controller | Option exercise | 4,075 | $115.67 |
| 2026-02-27 | Decker Robert J | VP Corporate Controller | Open market sale | 4,075 | $247.87 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-09-03 12:22 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-08-18 | 4 | 2026-08-17 | View on SEC.gov → |
| 2026-08-14 | 4 | 2026-08-13 | View on SEC.gov → |
| 2026-08-07 | 4 | 2026-08-05 | View on SEC.gov → |
| 2026-08-07 | 4 | 2026-08-06 | View on SEC.gov → |
| 2026-08-04 | 8-K | 2026-08-04 | View on SEC.gov → |
| 2026-07-29 | 8-K | 2026-07-29 | View on SEC.gov → |
| 2026-07-28 | 8-K | 2026-07-27 | View on SEC.gov → |
| 2026-07-23 | 10-Q | 2026-06-28 | View on SEC.gov → |
| 2026-07-21 | 4 | 2026-07-20 | View on SEC.gov → |
| 2026-07-15 | 8-K | 2026-07-15 | View on SEC.gov → |
| 2026-06-12 | 4 | 2026-06-11 | View on SEC.gov → |
| 2026-06-11 | 4 | 2026-06-09 | View on SEC.gov → |
Recent news
Headlines about JNJ (Johnson & Johnson). Links open the publisher — we don’t host full articles.
-
Amgen Stock Signals Its Confidence. The Market Agrees.
Yahoo · 2026-09-02 -
Sector Update: Healthcare Stocks Advance Late Afternoon
Yahoo · 2026-09-02 -
ISRG Stock: The Best House On The Block Costs The Most
Yahoo · 2026-09-02 -
Discover which dow jones stocks are making waves on Wednesday.
ChartMill · 2026-09-02 -
The Wide Divide Priced Into Boston Scientific Stock
Yahoo · 2026-09-02 -
Sector Update: Healthcare Stocks Advance Wednesday Afternoon
Yahoo · 2026-09-02 -
How Did Merck Stock Beat The Market With Slowing Sales?
Yahoo · 2026-09-02 -
J&J Jumps as UBS Lifts Its Target to $320
Yahoo · 2026-09-02
No headlines in this category right now — try “All”.